Melatonin and its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (afmk) enhance chemosensitivity to gemcitabine in pancreatic carcinoma cells (PANC-1)

Leja-Szpak, Anna; Nawrot-Porąbka, Katarzyna; Góralska, Marta; Jastrzębska, Martyna; Link-Lenczowski, Paweł; Bonior, Joanna; Pierzchalski, Piotr; Jaworek, Jolanta

doi:10.1016/j.pharep.2018.05.007

Cited by 14 publications

(11 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TLC and chromatography were performed with Qingdao silica gel GF254 and H60 (Qingdao Haiyang Chemical Co. Ltd, China), respectively. 1 H (300 and 800 M Hz) and 13C (75 and 200 MHz) NMR spectra were recorded on Bruker AMX-300 and AMX-800 spectrometer, while DMSO-d6 and TMS (Sigma) were used as the solvent and the internal standard, respectively. Electrospray ionization mass spectra (ESI-MS) were recorded on a ZQ 2000 mass spectrometer (Waters, USA) or a 9.4 T SolariX Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer (Bruker, USA) with ESI/matrix-assisted laser desorption/ionization (MALDI) dual ion source.…”

Section: Methodsmentioning

confidence: 99%

“…Gemcitabine has been used as a chemotherapeutic drug over 20 years, and it is a standard treatment choice for the locally advanced cancer, metastatic pancreatic cancer, breast cancer and ovarian cancer 1–6. The combinations of gemcitabine with the other drugs including oxaliplatin, irinotecan, miR-345, nab-paclitaxel, RT11-i antibody, metformin, ginkgolide B and melatonin are approved been able to enhance the efficacy of gemcitabine in the treatment of pancreatic cancer 7–13. Thus the combination of gemcitabine with platinum, carboplatin, sorafenib, paclitaxel, cisplatin plus bevacizumab and docetaxel is used for bladder cancer and muscle-invasive bladder cancer,7,14 advanced breast cancer,15 germ cell cancer,16 metastatic or unresectable transitional-cell carcinoma,17 recurrent urothelial carcinoma of bladder,18 concomitant primary lung cancer and metastatic pulmonary colorectal cancer19 and soft tissue sarcomas,20 respectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine</p>

Liu¹,

Mao²,

Zhang³

et al. 2019

IJN

View full text Add to dashboard Cite

BackgroundGemcitabine has been widely used as a chemotherapeutic drug. However, drug resistance, short half-life and side effects seriously decrease its chemotherapeutic efficacy.PurposeThe object of preparing RGDV-gemcitabine was to prolong the half-life, to overcome drug resistance and to eliminate bone marrow toxicity of gemcitabine.MethodsArg-Gly-Asp-Val was coupled with gemcitabine, forming 4-(Arg-Gly-Asp-Val-amino)-1-[3,3-difluoro-4-hydroxy-5-(hydroxylmethyl)oxo-lan-2-yl]pyrimidin-2-one (RGDV-gemcitabine) involving 9-step reactions. The advantages of RGDV-gemcitabine to gemcitabine were demonstrated by a series of assays, such as in vitro half-life assay, in vitro drug resistance assay, in vivo anti-tumor assay, in vivo kidney toxicity assay, in vivo liver toxicity assay and in vivo marrow toxicity assay. The nano-features of RGDV-gemcitabine were visualized by TEM, SEM and AFM images. The tumor-targeting action and release of RGDV-gemcitabine were evidenced by FT-MS spectra.ResultsHalf-life and anti-tumor activity of RGDV-gemcitabine were 17-fold longer and 10-fold higher than that of gemcitabine, respectively. RGDV-gemcitabine, but not gemcitabine, showed no kidney toxicity, no liver toxicity, no marrow toxicity and no drug resistance. The advantages attributed to the nanofeatures of RGDV-gemcitabine were targeting tumor tissue and releasing gemcitabine in tumor tissue.ConclusionRGDV-gemcitabine successively overcame the defects of gemcitabine and provided a practical strategy of nano-medicine.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

<p>RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine</p>

Liu¹,

Mao²,

Zhang³

et al. 2019

IJN

View full text Add to dashboard Cite

show abstract

“…Moreover, melatonin and its metabolite N1-acetyl-N2-formyl-5- methoxykynuramine (AFMK) have been observed to enhance chemosensitivity to gemcitabine in pancreatic carcinoma cells (PANC-1). Melatonin and the co-administration of metabolite N1-acetyl-N2-formyl-5-methoxykynuramine can improve the anti-tumor effect of gemcitabine in PANC-1 cells by enhancing the apoptotic pathway 54. Melittin also induced long non-coding RNA proliferation and migration of pancreatic ductal adenocarcinoma 55.…”

Section: Molecular Pathwaysmentioning

confidence: 98%

Update on current pancreatic treatments: from molecular pathways to treatment

et al. 2019

View full text Add to dashboard Cite

Pancreatic cancer is still diagnosed at a late stage although we have novel diagnostic tools. Pancreatic cancer chemotherapy treatment resistance is observed and therefore novel treatments are in need. Anti-cancer stem cell therapy, combination of chemotherapy and/or radiotherapy with immunotherapy, proteins/enzymes and gene therapy are currently under evaluation. Targeted treatment with tyrosine kinase inhibitors is also administered and novel inhibitors are also under evaluation. In the current review we present recent data from our search within the year 2018.

show abstract

“…It reduces radiation-induced DNA damage, oxidative stress in mitochondria, lipid peroxidation, inflammatory response and apoptosis [152]. On the other hand, melatonin and its metabolite enhance the sensitivity of cancer cells to anticancer drug [153]. Clinical studies indicate that the administration of melatonin during chemotherapy significantly increases the survival rate and objective tumor regression [154] and reduces some chemotherapy-induced side effects, such as myelosuppression, neurotoxity thrombocytopenia, cardiotoxocity and oral mucositis [154,155].…”

Section: Management Of Oral Mucositismentioning

confidence: 99%

Potential Therapeutic Effects of Gut Hormones, Ghrelin and Obestatin in Oral Mucositis

Stempniewicz

Ceranowicz

Warzecha

2019

IJMS

View full text Add to dashboard Cite

Chemotherapy and/or head and neck radiotherapy are frequently associated with oral mucositis. Oral pain, odynophagia and dysphagia, opioid use, weight loss, dehydration, systemic infection, hospitalization and introduction of a feeding tube should be mentioned as the main determinated effect of oral mucositis. Oral mucositis leads to a decreased quality of life and an increase in treatment costs. Moreover, oral mucositis is a life-threatening disease. In addition to its own direct life-threatening consequences, it can also lead to a reduced survival due to the discontinuation or dose reduction of anti-neoplasm therapy. There are numerous strategies for the prevention or treatment of oral mucositis; however, their effectiveness is limited and does not correspond to expectations. This review is focused on the ghrelin and obestatin as potentially useful candidates for the prevention and treatment of chemo- or/and radiotherapy-induced oral mucositis.

show abstract

Melatonin and its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (afmk) enhance chemosensitivity to gemcitabine in pancreatic carcinoma cells (PANC-1)

Cited by 14 publications

References 51 publications

<p>RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine</p>

<p>RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine</p>

Update on current pancreatic treatments: from molecular pathways to treatment

Potential Therapeutic Effects of Gut Hormones, Ghrelin and Obestatin in Oral Mucositis

Contact Info

Product

Resources

About